Pharma Equity Group A/S (PEG.CO)
DKK 0.18
(-2.17%)
DKK 0.18
(-2.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -24.6 Million DKK | -807.36% |
| 2022 | 3.47 Million DKK | -35.48% |
| 2021 | 5.39 Million DKK | 116.4% |
| 2020 | -32.87 Million DKK | -128.03% |
| 2019 | -14.41 Million DKK | -86.92% |
| 2018 | -7.71 Million DKK | -4457.63% |
| 2017 | 177 Thousand DKK | 117.1% |
| 2016 | -1.03 Million DKK | 62.68% |
| 2015 | -2.77 Million DKK | 53.24% |
| 2014 | -5.93 Million DKK | 95.82% |
| 2013 | -141.82 Million DKK | -227.7% |
| 2012 | -43.27 Million DKK | -154.91% |
| 2011 | -16.97 Million DKK | -1099.86% |
| 2010 | -1.41 Million DKK | 88.24% |
| 2009 | -12.03 Million DKK | 87.01% |
| 2008 | -92.66 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.17 Million DKK | 44.88% |
| 2024 Q2 | -5.86 Million DKK | 18.26% |
| 2023 Q4 | -13 Million DKK | -196.08% |
| 2023 Q1 | -2.86 Million DKK | -127.52% |
| 2023 Q2 | -4.34 Million DKK | -51.8% |
| 2023 Q3 | -4.39 Million DKK | -1.08% |
| 2023 FY | -24.6 Million DKK | -807.36% |
| 2022 Q4 | 10.4 Million DKK | 542.54% |
| 2022 FY | 3.47 Million DKK | -35.48% |
| 2022 Q2 | -2461.00 DKK | 0.0% |
| 2022 Q3 | -2.35 Million DKK | -95430.27% |
| 2021 FY | 5.39 Million DKK | 116.4% |
| 2020 FY | -32.87 Million DKK | -128.03% |
| 2019 FY | -14.41 Million DKK | -86.92% |
| 2018 FY | -7.71 Million DKK | -4457.63% |
| 2017 FY | 177 Thousand DKK | 117.1% |
| 2016 Q1 | -371 Thousand DKK | 67.77% |
| 2016 FY | -1.03 Million DKK | 62.68% |
| 2016 Q2 | -210 Thousand DKK | 43.4% |
| 2015 FY | -2.77 Million DKK | 53.24% |
| 2015 Q4 | -1.15 Million DKK | -42.45% |
| 2015 Q3 | -808 Thousand DKK | -67.29% |
| 2015 Q2 | -483 Thousand DKK | -51.41% |
| 2015 Q1 | -319 Thousand DKK | 66.03% |
| 2014 Q4 | -939 Thousand DKK | -651.2% |
| 2014 Q1 | -3.3 Million DKK | 95.06% |
| 2014 FY | -5.93 Million DKK | 95.82% |
| 2014 Q2 | -1.56 Million DKK | 52.81% |
| 2014 Q3 | -125 Thousand DKK | 91.99% |
| 2013 Q2 | -63.95 Million DKK | -1386.36% |
| 2013 Q4 | -66.91 Million DKK | -905.92% |
| 2013 Q3 | -6.65 Million DKK | 89.6% |
| 2013 Q1 | -4.3 Million DKK | 86.09% |
| 2013 FY | -141.82 Million DKK | -227.7% |
| 2012 Q3 | -4.37 Million DKK | 13.43% |
| 2012 Q2 | -5.04 Million DKK | -72.23% |
| 2012 FY | -43.27 Million DKK | -154.91% |
| 2012 Q1 | -2.93 Million DKK | 58.36% |
| 2012 Q4 | -30.93 Million DKK | -607.78% |
| 2011 Q2 | -3.45 Million DKK | -0.67% |
| 2011 Q3 | -3.05 Million DKK | 11.58% |
| 2011 FY | -16.97 Million DKK | -1099.86% |
| 2011 Q1 | -3.43 Million DKK | -326.02% |
| 2011 Q4 | -7.03 Million DKK | -130.48% |
| 2010 FY | -1.41 Million DKK | 88.24% |
| 2010 Q4 | 1.51 Million DKK | 208.2% |
| 2010 Q3 | -1.4 Million DKK | 8.24% |
| 2010 Q2 | -1.52 Million DKK | -214.61% |
| 2010 Q1 | -486 Thousand DKK | 79.17% |
| 2009 Q2 | -4.24 Million DKK | 0.0% |
| 2009 Q3 | -60 Thousand DKK | 98.59% |
| 2009 FY | -12.03 Million DKK | 87.01% |
| 2009 Q4 | -2.33 Million DKK | -3788.33% |
| 2008 FY | -92.66 Million DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ALK-Abelló A/S | 486 Million DKK | 105.064% |
| Bavarian Nordic A/S | 1.47 Billion DKK | 101.668% |
| Genmab A/S | 4.35 Billion DKK | 100.565% |
| Gubra A/S | -44.52 Million DKK | 44.729% |
| Novo Nordisk A/S | 83.68 Billion DKK | 100.029% |
| Orphazyme A/S | -26.04 Million DKK | 5.524% |
| Zealand Pharma A/S | -703.73 Million DKK | 96.503% |